PMC10400294_01
MR image of the liver lesion prior to third-line GTX therapy.
CRIONM2023-8751205.001.jpg
PMC10400294_01_CRIONM2023-8751205.001.jpg
fig1
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) in the second line starting in April 2020. Five months later, imaging demonstrated progression (Figure 1).